Trabodenoson and trabecular meshwork rejuvenation: A comprehensive review of clinical data.

This article sheds light on the root causes of the two pivotal Phase 3 clinical trials failures in patients with POAG or OH; it further highlights the discovery of MMP-2 in trabecular meshwork (TM) rejuvenation, which has strategic importance in long-term glaucoma patient care. EXPERT OPINION: Trabodenoson is a BID glaucoma eye drop with possible QD dose as maintenance. Its Phase 3 pivotal clinical trials failed at the wrong dose and dosing regimen because of the misinterpretation of the complex IOP results from the Phase 2 monotherapy and combination studies. The future development should focus on the TM benefits whilst unleashing its potential of neural protection through nanoparticle eye drops, medical coating and sustained release drug delivery. PMID: 33405971 [PubMed - as supplied by publisher]
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research